Smith L H, Oi R H
Obstet Gynecol Surv. 1984 Jun;39(6):346-60.
In summarizing the data on characterization of the immune system in the ovarian cancer patient, it is possible to conclude that both cellular and humoral immune responses occur in the presence of ovarian cancer. However, the specificity of such reactions is less certain. Although most of the tests outlined above are of doubtful utility in cancer immunodetection, data obtained from some studies support the assumption that there exist epithelial ovarian cancer-associated antigens which are expressed in tumors arising in different individuals, and that these antigens are the target of an immune response in many patients. It is unclear, however, how widely distributed such antigens are among normal tissues and other neoplasms. Direct characterization of ovarian cancer-associated antigens may provide more well-defined test antigens with which to assay individuals for a specific immune response. An immune response to specific cancer-associated antigens could precede the appearance of detectable levels of such antigens in the circulation.
在总结卵巢癌患者免疫系统特征的数据时,可以得出结论:在卵巢癌存在的情况下,细胞免疫和体液免疫反应都会发生。然而,此类反应的特异性尚不确定。尽管上述大多数检测方法在癌症免疫检测中的效用存疑,但一些研究获得的数据支持这样的假设,即存在上皮性卵巢癌相关抗原,这些抗原在不同个体发生的肿瘤中表达,并且这些抗原是许多患者免疫反应的靶标。然而,尚不清楚此类抗原在正常组织和其他肿瘤中的分布有多广泛。直接鉴定卵巢癌相关抗原可能会提供更明确的检测抗原,用以检测个体的特异性免疫反应。针对特定癌症相关抗原的免疫反应可能在循环中可检测到此类抗原水平出现之前就已发生。